Method for preparing heat-stable antibodies

The antibody is mutation through computer graphics and software simulation technology, which improves the thermal stability of the antibody, solves the stability of the antibody at different temperatures, and achieves efficient transformation of the antibody.

CN112786101BActive Publication Date: 2024-11-12CHINA AGRI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201911083366.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-11-07
Publication Date
2024-11-12
Estimated Expiration
2039-11-07

AI Technical Summary

Technical Problem

It is difficult for existing antibodies to improve their thermal stability during the transformation process, affecting their biological effects and chemical stability at different temperatures.

Method used

The spatial model of antibodies is constructed through computer graphics and other technologies, and the key amino acid sites are determined and site-oriented mutations are performed. Software simulation calculations are used to evaluate the changes in antibody binding energy before and after mutations, including P146W and G105I for the single-chain antibody scFv4C7 of sulfonamide drug. Mutations such as V144W, A72W, S149C improve their thermal stability.

Benefits of technology

The thermal stability of the antibody was improved, the Tm value was increased by 11.3℃, while maintaining the affinity of the antibody, providing an accurate and efficient method to modify the thermal stability of the antibody.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002264630360000031
    Figure BDA0002264630360000031
  • Figure BDA0002264630360000042
    Figure BDA0002264630360000042
  • Figure BDA0002264630360000051
    Figure BDA0002264630360000051
Patent Text Reader

Abstract

The present invention provides a method for preparing a thermostable antibody, comprising: 1) constructing a spatial model of the antibody and evaluating the model; 2) determining the sites of key amino acids and performing site-directed mutation; 3) evaluating the changes in antibody binding energy before and after mutation by software simulation calculation. Further, the present invention takes the sulfonamide single-chain antibody scFv4C7 as an example, and theoretically explores the key factors affecting the thermostability of antibodies through sequence alignment, structural simulation and optimization, virtual amino acid mutation, etc., and combined with the results of biological experiments, the antibody mutants obtained by this method have improved their thermostability to varying degrees, providing a theoretical basis for the modification of the thermostability of antibody molecules.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of structural biology, bioinformatics and immunology, and in particular to a method for preparing a thermally stable antibody. Background Art

[0002] With the continuous progress of molecular biology technology, antibody structure and function research, genetic recombinant antibodies (third generation antibodies) have been widely used in the fields of immunodiagnosis and treatment, drug development and environmental analysis. However, in the process of antibody modification, the problem of improving its stability has not been solved. The stability and biological effect of protein depend not only on the primary sequence, but more importantly on its spatial conformation. With the development of computer chemistry, there are attempts to design antibodies using computer methods to enhance their thermal stability and chemical stability and reduce the aggregation field of IgG constant domains. Summary of the invention

[0003] The object of the present invention is to provide a method for preparing a thermostable antibody.

[0004] In order to achieve the purpose of the present invention, in the first aspect, the present invention provides a method for improving the thermal stability of an antibody, specifically using computer graphics and other technologies to improve the thermal stability of an antibody. The method comprises the following steps:

[0005] 1) For antibodies with known sequences, use biological software to construct a spatial model of the antibody and evaluate the model (evaluate the rationality of the model);

[0006] 2) Determine the sites of key amino acids and perform site-directed mutagenesis;

[0007] 3) Evaluate the changes in antibody binding energy before and after mutation through software simulation calculation.

[0008] Furthermore, the antibody is derived from humans, mice, rats, rabbits, pigs, sheep, camels, alpacas, cattle or sharks.

[0009] Furthermore, the antibody is IgG, Fab, scFv or Nanobody, etc.

[0010] Furthermore, the selected mutation region may be the variable region and / or constant region of the antibody.

[0011] In a second aspect, the present invention provides a mutant of a sulfonamide single-chain antibody scFv4C7, wherein the mutant comprises at least one of the following mutations ① to ⑤ of the single-chain antibody scFv4C7:

[0012] ①P146W mutation;

[0013] ②G105I mutation;

[0014] ③V144W mutation;

[0015] ④A72W mutation;

[0016] ⑤S149C mutation.

[0017] Preferably, the mutant contains five mutation sites ① to ⑤.

[0018] In the present invention, the amino acid sequence of the sulfonamide single-chain antibody scFv4C7 is shown in SEQ ID NO: 1. The amino acid sequence of the mutant containing the above five mutation sites is shown in SEQ ID NO: 2.

[0019] In a third aspect, the present invention provides a nucleic acid molecule encoding the mutant.

[0020] In a fourth aspect, the present invention provides biological materials containing the nucleic acid molecule, wherein the biological materials include but are not limited to recombinant DNA, expression cassettes, transposons, plasmid vectors, phage vectors, viral vectors, engineered bacteria or transgenic cell lines.

[0021] In a fifth aspect, the present invention provides a sulfonamide drug detection reagent or kit, the active ingredient of which is the above-mentioned mutant.

[0022] In a sixth aspect, the present invention provides any of the following uses of the mutant:

[0023] 1) Used for the detection of sulfonamide drugs;

[0024] 2) Used for preparing sulfonamide drug detection reagents or kits.

[0025] In the present invention, the sulfonamide drugs include sulfonamide, sulfacetamide, sulfaguanidine, sulfaphenazole, phthaleinsulfathiazole, sulfadimethoxazole, sulfathiazole, sulfamethoxazole, sulfadimethoxazole, sulfamethoxazole, sulfamethizole, sulfadimethoxazole, sulfadimethoxazole, sulfadimethoxazole, sulfanitrophenyl, sulfasalazine, sulfapyridine, sulfachloropyridazine, sulfamethoxypyridazine, sulfaethoxypyridazine, sulfaquinoxaline, sulfachloropyrazine, sulfadoxine, sulfadiazine, sulfadimethox ...

[0026] The present invention takes the single-chain antibody (scFv4C7) of sulfonamide drugs as an example, constructs a spatial model of the antibody, evaluates the rationality of the model, determines the key amino acids that affect the thermal stability of the antibody in the non-CDR region by amino acid site-directed mutagenesis, and then selects the seven amino acids A72, G105, V144, P146, S149, G198, and I200 on the single-chain antibody scFv4C7 for site-directed mutagenesis according to the polarity, non-polarity, and charge similarity principles of the mutated amino acids, and determines the five mutation sites of P146W (representing the mutation of Pro to Trp at position 146), G105I, V144W, A72W, and S149C that improve the thermal stability of the antibody by the change in mutation energy. The affinity of the antibody after mutation is not significantly affected, the mutation energy is reduced by 9.95 kcal / mol, and the Tm value is increased by 11.3 ° C. The antibody stability evolution method provided by the present invention is suitable for improving the thermal stability of antibodies.

[0027] By means of the above technical solution, the present invention has at least the following advantages and beneficial effects:

[0028] The present invention provides a precise and efficient method for improving the thermal stability of a single-chain antibody. Taking the sulfonamide single-chain antibody scFv4C7 as an example, the key factors affecting the thermal stability of the antibody are theoretically explored through sequence alignment, structure simulation and optimization, virtual amino acid mutation, etc., and combined with the results of biological experiments, the thermal stability of the antibody mutants obtained by the method is improved to varying degrees, providing a theoretical basis for the modification of the thermal stability of antibody molecules. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 The diagram shows the amino acid sequence of the light chain VL and heavy chain VH of the single-chain antibody scFv4C7 of the present invention.

[0030] Figure 2 This is a spatial model diagram of the single-chain antibody scFv4C7 of the present invention.

[0031] Figure 3 It is a Ramachandran plot of the spatial conformation of the single-chain antibody scFv4C7 of the present invention.

[0032] Figure 4 The Profile-3D analysis result of the spatial conformation of the single-chain antibody scFv4C7 of the present invention.

[0033] Figure 5 This is the Tm curve of the single-chain antibody scFv4C7 before mutation of the present invention.

[0034] Figure 6 This is the Tm curve of the mutated antibody MscFv4C7 of the present invention.

[0035] Figure 7This is a diagram showing the energy changes of some amino acid mutations of the present invention.

[0036] Figure 8 The binding energy changes between the single-chain antibody scFv4D7 of the present invention and the mutated antibody MscFv4C7. DETAILED DESCRIPTION

[0037] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are all commercially available products.

[0038] Example 1 Improving the thermal stability of antibodies using computer graphics and other technologies

[0039] In this example, the amino acid sequences of the light chain variable region VL and the heavy chain variable region VH of the existing sulfonamide drug single-chain antibody scFv4C7 (SEQ ID NO: 1) are used as model antibodies. The amino acid sequence of scFv4C7 can be annotated using the ModelAntibody module in the Discovery Studio 2019 software, such as Figure 1 As shown, the hypervariable regions of VH are: CDR1: 26GYSITSGYS; CDR2: 52IHYSGST; CDR3: 97ARYGGY, and the hypervariable regions of VL are: CDR1: 27QSLLDSDGKTY; CDR2: 55LVS; CDR3: 94WQGTHFPQT.

[0040] According to the analysis of ExPASy database, scFv4C7 is composed of 245 amino acids (Table 1), with a molecular weight of about 26KD and a theoretical isoelectric point of 8.62. It is an alkaline protein with a positive charge in a neutral environment. The specific amino acid composition of the scFv is shown in Table 1. There are 17 negatively charged amino acids (Asp and Glu) and 20 positively charged amino acids (Arg and Lys). The molar elimination coefficient is 52370-52620M -1 cm -1 The instability coefficient in water is 42.70, indicating that the scFv4C7 is an unstable protein.

[0041] Table 1 Amino acid composition of single chain antibody scFv4C7

[0042]

[0043]

[0044] Based on the antibody structure information databases such as NCBI, Kabat, and IMGT, the VL and VH spatial structure information of scFv4C7 was imported into the Molecular Builder module in Discovery Studio 2019 software for molecular display, and the spatial model of scFv4C7 was constructed. The optimal model was selected according to the PDF value or DOPE value, such as Figure 2 shown.

[0045] Then, the conformational rationality of scFv4C7 was evaluated using Ramachandran Plot and Profile-3D. Figure 3 ) The model structure was evaluated and 91.02% of the 245 amino acids were in the allowed or optimal regions, and the number of amino acids with unreasonable conformations did not exceed 9%, indicating that the three-dimensional structure of scFv4C7 was reasonable and credible. Profile-3D diagram shows ( Figure 4 ), only 7 amino acids have a Verify Score less than 0, indicating that the credibility of the homology modeling of scFv4C7 is high.

[0046] Further improving the thermal stability of scFv by site-directed amino acid mutation is achieved without reducing the affinity of antibodies and small molecule drugs. The mutation sites are mainly located in the non-CDR region. Theoretically, without affecting the spatial conformation of the antibody, the change of these residues will not affect the interaction with the antigen.

[0047] Polar amino acids include: Threonine (Thr) Serine (Ser) Cysteine ​​(Cys) Asparagine (Asn) Glutamine (Gln) Tyrosine (Tyr). Positively charged amino acids include: Lysine (Lys) Arginine (Arg) Histidine (His). Negatively charged amino acids include: Aspartic acid (Asp) Glutamic acid (Glu). Non-polar amino acids include: Glycine (Gly) Alanine (Ala) Valine (Val) Leucine (Leu) Isoleucine (Ile) Phenylalanine (Phe) Tryptophan (Trp) Methionine (Met) Proline (Pro). Generally speaking, non-polar amino acids are usually inside proteins, and polar amino acids are usually on the surface of proteins. Therefore, amino acid mutations should be performed between similar amino acids to minimize the impact of mutations on antibody conformation.

[0048] The single-chain antibody scFv4C7 was assigned the CHARMm force field using Discovery Studio 2019 software, and then single-point mutations were performed on the amino acids in the non-CDR regions to determine the key amino acids that affect the thermal stability of the antibody, which are A72, G105, V144, P146, S149, G198, and I200 located in the non-CDR regions.

[0049] These 7 amino acid sites were named mutations and mutated to other 19 amino acids using the Calculate Mutation Energy (Stability) function in the Design Protein module of Discovery Studio 2019 software. The results showed (Table 2, Figure 7 ), when P146W (representing the mutation of position 146 from Pro to Trp), G105I, V144W, A72I and S149C, the mutation energy is less than -1, and the corresponding mutation effect is improved stability, indicating that mutations at these five sites can improve the thermal stability of scFv4C7. When these five amino acids are mutated simultaneously, the mutation energy can be reduced by up to -9.95 kcal / mol (Table 3), and the mutant is named MscFv4C7 (SEQ ID NO: 2).

[0050] Table 2 Mutational energy changes of single-point mutations of single-chain antibody scFv4D7

[0051]

[0052]

[0053] Note: The mutation of the first seven amino acids can reduce the protein content most significantly, and only some results are selected from the eighth position onwards.

[0054] Table 3 Mutational energy changes of multiple mutations of single-chain antibody scFv4D7

[0055]

[0056] Note: The total number of mutations was about 5,000, and the mutations were performed in batches. The data shown in the table are the data of the batch containing the amino acid mutations that can reduce the most significant mutation energy.

[0057] By performing site-directed mutagenesis on five amino acid sites, the CalculateBinding Energies module in Discovery Studio 2019 can calculate that the binding energy does not decrease significantly after mutation ( Figure 8 ), and even some of the binding energies have been greatly improved, indicating that some of the affinities have been improved.

[0058] The expressed scFv4C7 and mutant antibody MscFv4C7 were measured by the protein stability analyzer Uncle, and the Tm value before mutation was only 63.1℃ ( Figure 5 ), the Tm value after mutation was 74.4℃( Figure 6), the Tm value increased by 11.3°C. Since all amino acid mutations are carried out in the framework region of the antibody, which is far away from the antibody-antigen binding region, the affinity of the single-chain antibody is very small, and the affinity of the single-chain antibody is not reduced while the thermal stability is improved. Therefore, the present invention provides a method that can improve the thermal stability of the single-chain antibody without reducing the affinity of the single-chain antibody, providing a theoretical basis for the modification of the thermal stability of the antibody molecule.

[0059] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention. Sequence Listing <120> Method for preparing heat-stable antibodies <130> KHP191115473.2 <160> 2 <170> SIPOSequenceListing 1.0 <210> 1 <211> 245 <212> PRT <213> Artificial Sequence <400> 1 Asp Val Val Met Thr Gln Thr Pro Ile Thr Leu Ser Val Thr Ile Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Arg Val Pro 50 55 60 Asp Arg Phe Thr Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 115 120 125 Gly Gly Gly Ser Asp Val Gln Leu Arg Glu Ser Gly Pro Asp Leu Val 130 135 140 Thr Pro Ser Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser 145 150 155 160 Ile Thr Ser Gly Tyr Ser Trp His Trp Asn Arg Gln Phe Pro Gly Asn 165 170 175 Lys Leu Glu Trp Met Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr 180 185 190 Asn Pro Ser Leu Arg Gly Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys 195 200 205 Asn Gln Phe Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala 210 215 220 Thr Tyr Tyr Cys Ala Arg Tyr Gly Gly Tyr Trp Gly Gln Gly Thr Ser 225 230 235 240 Val Thr Val Ser Ser 245 <210> 2 <211> 245 <212> PRT <213> Artificial Sequence <400> 2 Asp Val Val Met Thr Gln Thr Pro Ile Thr Leu Ser Val Thr Ile Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Arg Val Pro 50 55 60 Asp Arg Phe Thr Gly Ser Gly Trp Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Gln Thr Phe Gly Ile Gly Thr Lys Leu Glu Ile Lys 100 105 110 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 115 120 125 Gly Gly Gly Ser Asp Val Gln Leu Arg Glu Ser Gly Pro Asp Leu Trp 130 135 140 Thr Trp Ser Gln Cys Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser 145 150 155 160 Ile Thr Ser Gly Tyr Ser Trp His Trp Asn Arg Gln Phe Pro Gly Asn 165 170 175 Lys Leu Glu Trp Met Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr 180 185 190 Asn Pro Ser Leu Arg Gly Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys 195 200 205 Asn Gln Phe Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala 210 215 220 Thr Tyr Tyr Cys Ala Arg Tyr Gly Gly Tyr Trp Gly Gln Gly Thr Ser 225 230 235 240 Val Thr Val Ser Ser 245

Claims

1. A mutant of sulfonamide single-chain antibody scFv4C7, characterized in that: The mutant comprises at least one of the following mutations ① to ⑤ of the single-chain antibody scFv4C7: ①P146W mutation; ②G105I mutation; ③V144W mutation; ④A72W mutation; ⑤S149C mutation; The amino acid sequence of the single-chain antibody scFv4C7 is shown in SEQ ID NO:

1.

2. The mutant according to claim 1, characterized in that The mutant comprises ①~⑤ mutations.

3. A nucleic acid molecule encoding the mutant according to claim 1 or 2.

4. A biological material containing the nucleic acid molecule according to claim 3, wherein the biological material is a recombinant DNA, an expression cassette, a transposon, a plasmid vector, a viral vector, an engineered bacterium or a transgenic cell line.

5. A sulfonamide drug detection reagent or kit, characterized in that: The active ingredient is the mutant according to claim 1 or 2.

6. Any of the following uses of the mutant according to claim 1 or 2: 1) Used for the detection of sulfonamide drugs; 2) Used for preparing sulfonamide drug detection reagents or kits.

7. The use according to claim 6, characterized in that: The sulfonamide drugs include sulfonamide, sulfacetamide, sulfaguanidine, sulfaphenazole, phthalic acid sulfathiazole, sulfadimethoxazole, sulfathiazole, sulfamethoxazole, sulfadimethoxazole, sulfamethoxazole, sulfamethizole, sulfadimethoxazole, sulfadimethoxazole, sulfanitrophenyl, sulfasalazine, sulfapyridine, sulfachloropyridazine, sulfamethoxypyridazine, sulfaethoxypyridazine, sulfaquinoxaline, sulfachloropyrazine, sulfadoxine, sulfadiazole, sulfadimethoxine, sulfadimethoxine, sulfadimethoxine, sulfadimethoxine, sulfadimethoxine, sulfadimethoxine, and sulfadimethoxine.